FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma By Ogkologos - June 6, 2025 562 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR How a Musician Copes With Life With Metastatic Breast Cancer March 17, 2021 Meet Rosalie: St. Jude Children’s Research Hospital’s New Service Dog For... October 19, 2021 An unexpected find: clues about the genetics of children’s cancer found... April 6, 2021 Survival According Circulating Tumour DNA Status in the Study of Adjuvant... December 10, 2020 Load more HOT NEWS Data from a Large Cohort of Patients with mRCC Demonstrate the... FDA Approves Trastuzumab Deruxtecan for Any HER2-Positive Solid Cancer Studies Show Immunotherapy Improves Long-Term Survival in Growing Number of Cancers NBC’s Kristen Dahlgren Discusses The Unexpected Breast Cancer Symptom She Almost...
